{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-029341","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2026-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.534403+00:00","generated_at":"2026-05-16T06:26:45.398459+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Palvella makes corporate presentation available; no new specifics disclosed","bullets":["Presentation titled 'First-in-disease therapies for rare diseases' dated January 2026.","No financial results, clinical data, or guidance changes included in the provided excerpt.","Filing does not contain material new information beyond the presentation's availability."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-029341","json":"https://secwatch.observer/filing/0001193125-26-029341.json","markdown":"https://secwatch.observer/filing/0001193125-26-029341.md","text":"https://secwatch.observer/filing/0001193125-26-029341.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000119312526029341/0001193125-26-029341-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000119312526029341/pvla-20260129.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:26:45.398459+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}